Genetic analysis of low-grade adenosquamous carcinoma of the breast progressing to high-grade metaplastic carcinoma.

Breast cancer High-grade progression Low-grade adenosquamous carcinoma Metaplastic carcinoma Whole-genome sequencing

Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 29 06 2023
accepted: 07 08 2023
medline: 11 10 2023
pubmed: 31 8 2023
entrez: 31 8 2023
Statut: ppublish

Résumé

Low-grade adenosquamous carcinoma (LGASC) is a rare type of metaplastic carcinoma of the breast (MBC) with an indolent clinical course. A few LGASC cases with high-grade transformation have been reported; however, the genetics underlying malignant progression of LGASC remain unclear. We performed whole-genome sequencing analysis on five MBCs from four patients, including one case with matching primary LGASC and a lymph node metastatic tumor consisting of high-grade MBC with a predominant metaplastic squamous cell carcinoma component (MSC) that progressed from LGASC and three cases of independent de novo MSC. Unlike de novo MSC, LGASC and its associated MSC showed no TP53 mutation and tended to contain fewer structural variants than de novo MSC. Both LGASC and its associated MSC harbored the common GNAS c.C2530T:p.Arg844Cys mutation, which was more frequently detected in the cancer cell fraction of MSC. MSC associated with LGASC showed additional pathogenic deletions of multiple tumor-suppressor genes, such as KMT2D and BTG1. Copy number analysis revealed potential 18q loss of heterozygosity in both LGASC and associated MSC. The frequency of SMAD4::DCC fusion due to deletions increased with progression to MSC; however, chimeric proteins were not detected. SMAD4 protein expression was already decreased at the LGASC stage due to unknown mechanisms. Not only LGASC but also its associated high-grade MBC may be genetically different from de novo high-grade MBC. Progression from LGASC to high-grade MBC may involve the concentration of driver mutations caused by clonal selection and inactivation of tumor-suppressor genes.

Identifiants

pubmed: 37650999
doi: 10.1007/s10549-023-07078-9
pii: 10.1007/s10549-023-07078-9
pmc: PMC10564816
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

563-573

Subventions

Organisme : The Ministry of Education, Culture, Sports, Science and Technology
ID : JP16H06277
Organisme : The Ministry of Education, Culture, Sports, Science and Technology
ID : JP22H04923 (CoBiA)

Informations de copyright

© 2023. The Author(s).

Références

Genome Biol. 2011;12(4):R41
pubmed: 21527027
Histopathology. 2014 Jul;65(1):9-23
pubmed: 24382117
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Clin Cancer Res. 2017 Jul 15;23(14):3859-3870
pubmed: 28153863
Nat Protoc. 2018 Jun;13(6):1488-1501
pubmed: 29844525
Nat Rev Cancer. 2015 Jun;15(6):334-46
pubmed: 25998713
Am J Surg Pathol. 1987 May;11(5):351-8
pubmed: 3578645
Mod Pathol. 2003 Sep;16(9):893-901
pubmed: 13679453
PLoS One. 2019 Apr 16;14(4):e0209134
pubmed: 30990809
Am J Hum Genet. 2003 Oct;73(4):748-67
pubmed: 13680524
Mod Pathol. 2010 Jul;23(7):951-60
pubmed: 20453835
J Pathol Clin Res. 2017 Mar 20;3(2):115-122
pubmed: 28451460
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
Histopathology. 2016 Jun;68(7):1030-9
pubmed: 26497122
J Clin Pathol. 2013 Jun;66(6):506-11
pubmed: 23268316
Am J Surg Pathol. 1993 Mar;17(3):248-58
pubmed: 8434705
Gigascience. 2021 May 21;10(5):
pubmed: 34018555
Am J Surg Pathol. 2012 Jul;36(7):1009-20
pubmed: 22446941
J Cell Physiol. 2010 Jan;222(1):66-72
pubmed: 19746446
J Pathol. 2019 Feb;247(2):214-227
pubmed: 30350370
Histopathology. 2018 Aug;73(2):273-283
pubmed: 29537649
Breast Cancer Res Treat. 2016 Feb;156(1):21-32
pubmed: 26907767
Tumour Biol. 2014 Apr;35(4):3317-26
pubmed: 24272202
Histopathology. 2000 Mar;36(3):203-9
pubmed: 10692021
Arch Pathol Lab Med. 2019 Dec;143(12):1492-1496
pubmed: 31765246
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016

Auteurs

Kae Kawachi (K)

Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan.
Department of Pathology, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, Japan.

Xiaoyan Tang (X)

Department of Pathology, Nihon University Hospital, 1-6 Kandasurugadai, Chiyoda-ku, Tokyo, Japan.

Rika Kasajima (R)

Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan.
Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.

Takashi Yamanaka (T)

Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan.

Eigo Shimizu (E)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.

Kotoe Katayama (K)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.

Rui Yamaguchi (R)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.
Division of Cancer Systems Biology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Japan.
Division of Cancer Informatics, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-ku, Nagoya, Japan.

Kazuaki Yokoyama (K)

Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Kiyoshi Yamaguchi (K)

Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.

Yoichi Furukawa (Y)

Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.

Satoru Miyano (S)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.
Department of Integrated Data Science, Medical and Dental Data Science Center, Tokyo Medical and Dental University, 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo, Japan.

Seiya Imoto (S)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.

Emi Yoshioka (E)

Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan.

Kota Washimi (K)

Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan.

Yoichiro Okubo (Y)

Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan.

Shinya Sato (S)

Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan.

Tomoyuki Yokose (T)

Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan.

Yohei Miyagi (Y)

Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Aasahi-ku, Yokohama, Japan. miyagi@gancen.asahi.yokohama.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH